Short-term administration of an angiotensin-receptor antagonist in patients with impaired fasting glucose improves insulin sensitivity and increases free IGF-I

European Journal of Endocrinology

Volumn 155, Issue 2, 2006, Pages 293-296

  Zandbergen, Adrienne A M ^a   Lamberts, Steven W J ^a   Janssen, Joop A M J L ^a   Bootsma, Aart H ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; GLUCOSE; HEMOGLOBIN A1C; LIPID; LOSARTAN; SOMATOMEDIN BINDING PROTEIN 3; SOMATOMEDIN C;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTINUOUS INFUSION; CONTROLLED STUDY; CORRELATION ANALYSIS; CORRELATION COEFFICIENT; DIET RESTRICTION; DRUG DOSE REGIMEN; FEMALE; GLUCOSE BLOOD LEVEL; GLUCOSE HOMEOSTASIS; HEMOGLOBIN BLOOD LEVEL; HUMAN; IMPAIRED GLUCOSE TOLERANCE; INSULIN RESISTANCE; INSULIN SENSITIVITY; LIPID BLOOD LEVEL; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PATHOGENESIS; PRIORITY JOURNAL; PROPHYLAXIS; PROTEIN BLOOD LEVEL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SCORING SYSTEM; SHORT COURSE THERAPY;

ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; BLOOD GLUCOSE; BLOOD PRESSURE; DIABETES MELLITUS, TYPE 2; FASTING; FEMALE; GLUCOSE INTOLERANCE; HUMANS; INSULIN RESISTANCE; INSULIN-LIKE GROWTH FACTOR I; LOSARTAN; MALE; MIDDLE AGED; TREATMENT OUTCOME;

EID: 33747703643     PISSN: 08044643     EISSN: None     Source Type: Journal    
DOI: 10.1530/eje.1.02219     Document Type: Article

References (13)

1. Zandbergen AA, Baggen MG, Lamberts SW, Bootsma AH, de Zeeuw D & Ouwendijk RJ. Effect of losartan on microalbuminuria in normotensive patients with type 2 diabetes mellitus. A randomized clinical trial. Annals of Internal Medicine 2003 139 90-96.
2. Julius S, Kjeldsen SE, Weber M, Brunner HR, Ekman S, Hansson L, Hua T, Laragh J, McInnes GT, Mitchell L, Plat F, Schork A, Smith B & Zanchetti A. For the value trial group. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the value randomised trial. Lancet 2004 363 2022-2031.
3. Leiter LA & Lewanczuk RZ. Of the renin-angiotensin system and reactive oxygen species type 2 diabetes and angiotensin 11 inhibition. American Journal of Hypertension 2005 18 121-128.
4. Sandhu MS, Heald AH & Gibson JM. Circulating concentrations of insulin-like growth factor-I and development of glucose tolerance: a prospective observational study. Lancet 2002 359 1740-1745.
5. Zandbergen AA, Lamberts SW, Baggen MG, Janssen JA, Boersma E & Bootsma AH. The insulin-like growth factor I (IGF-1) system and the renal and haemodynamic effects of losartan in normotensive patients with type 2 diabetes mellitus. A randomised clinical trial. Clinical Endocrinology 2006 64 203-208.
6. Onder G, Penninx B, Balkrishnan R, Fried LP, Chaves PH, Williamson J, Carter C, Di Bari M, Guralnik JM & Pahor M. Relation between use of angiotensin-converting enzyme inhibitors and muscle strenght and physical function in older women: an observational study. Lancet 2002 359 926-930.
7. Alberti KG & Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications. Part I: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabetes Medicine 1998 15 539-553.
8. Bonora E, Targher G, Alberiche M, Bonadonna RC, Saggiani F, Zenere MB, Monauni T & Muggeo M. Horneostasis model assessment closely mirrors the glucose clamp technique in the assessment of insulin sensitivity. Diabetes Care 2000 23 57-63.
9. Blum WF & Breier BH. Radioimmunoassays for 1GFs and 1GFBPs. Growth Regulation 1994 4 (Suppl 1) 11-19.
10. Frystyk J, Ivarsen P, Stoving RK, Dall R, Bek T, Hagen C & Ørskov H. Determination of free insulin like growth factor-1 in human serum: comparison of ultrafiltration and direct immunoradiometric assay. Growth Hormone and IGF Research 2001 11 117-127.
11. Juul A, Holm K, Kastrup KW, Pedersen SA, Michaelsen KF, Scheike, T, Rasmussen S, Muller J & Skakkebaek NE Free insulin-like growth factor I serum levels in 1430 healthy children and adults and its diagnostic value in patients suspected of growth hormone deficiency. Journal of Clinical Endocrinology and Metabolism 1997 82 2497-2502.
12. Saukkonen T, Amin R, Williams RM, Fox C, Yuen KC, White MA, Umpleby AM, Acerini CL & Danger DB. Dose-dependent effects of recombinant human insulin-like growth factor (IGF)-I/IGF binding protein-3 complex on overnight growth hormone secretion and insulin sensitivity in type I diabetes. Journal of Clinical Endocrinology and Metabolism 2004 89 4634-4641.
13. Brink M, Wellen J, Delafontaine P & Angiotensin, II. causes weight loss and decreases circulating insulin-like growth factor I in rats through a pressor-independent mechanism. Journal of Clinical Investigation 1996 97 2509-2516.